Compare iShares MSCI Australia ETF (EWA) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Australia ETF vs Johnson & Johnson — how do they compare? iShares MSCI Australia ETF trades at $28.63, while Johnson & Johnson trades at $247.62 (market cap $594.63B). The key difference: Johnson & Johnson pays a 2.17% dividend while iShares MSCI Australia ETF pays none, and Johnson & Johnson is trading nearer its 52-week high, iShares MSCI Australia ETF nearer its low. Which is the better fit depends on your goals.
| EWA | JNJ | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $30.26 | $267.24 |
52-Week Low | $24.95 | $162.98 |
Market Cap | — | $594.63B |
Volume | — | 6,156,228 |
Enterprise Value | — | $627.57B |
Dividend Yield | — | 2.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWA trades at $28.625, down 0.3% with a bullish technical signal from moving averages. The stock shows neutral oscillator readings with RSI at 72.02 suggesting potential overbought conditions. Recent news highlights Australia's economic developments including fuel excise relief and tax reforms that may impact investor sentiment toward Australian-focused assets.
The outlook remains cautiously optimistic given the bullish technical setup, though limited fundamental data availability requires careful monitoring. Key risks include Australian economic sensitivity and market volatility from geopolitical tensions. Investors should await updated financial metrics for comprehensive fundamental assessment.
Johnson & Johnson (JNJ) trades at $249.42, down 1.75% over 24 hours, with a bullish technical signal from moving averages but bearish oscillators. The company reported Q2 2026 EPS of $2.90, beating estimates, and raised full-year guidance. Revenue grew 6.6% annually, supported by strong pharmaceutical sales. Analyst consensus is bullish with a $281 price target, and the stock offers a stable dividend with recent payouts of $1.34 per share.
Outlook remains positive due to robust fundamentals, innovation in medtech and pharmaceuticals, and dividend king status. Risks include patent expirations, regulatory pressures, and macroeconomic volatility. The current valuation at P/E 28.66 may limit near-term upside, but long-term growth prospects appear solid.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
